



(51) International Patent Classification:

A61K 31/48 (2006.01) *G01N 33/94* (2006.01)
G01N 30/72 (2006.01)

(21) International Application Number:

PCT/US2022/026274

(22) International Filing Date:

26 April 2022 (26.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/182,700 30 April 2021 (30.04.2021) US

(71) Applicant: **MIND MEDICINE, INC.** [US/US]; One World Trade Center, Suite 8500, New York, New York 10007 (US).

(72) Inventors: **LEVY, Daniel Emil**; 37 Lakewood Circle, San Mateo, California 84402 (US). **SCHNEIDER, Stephen E.**; 7405 Baystone Court, Raleigh, North Carolina 27615 (US).

(74) Agent: **KOHN, Kenneth, I.**; KOHN & ASSOCIATES PLLC, 30500 Northwestern Highway, Suite 410, Farmington Hills, Michigan 48334 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: LSD SALT CRYSTAL FORMS




Fig. 1 – XRPD diffractogram of D-LSD Naphthalene-2-sulfonic acid salt

(57) Abstract: Polymorphic forms of lysergic acid diethyl amide (LSD) in crystalline salt forms. A pharmaceutical formulation of polymorphic forms of LSD in crystalline salt forms including pharmaceutically acceptable excipients. Polymorphic forms of LSD free-base. Polymorphic forms of a salt form of LSD.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*